| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 22,190 | 45,445 | 93,732 | 86,820 |
| Short-term investments | 148,702 | 145,499 | 148,065 | 176,053 |
| Prepaid expenses and other current assets (note 5) | 3,132 | 4,464 | 3,791 | 4,571 |
| Property and equipment held for sale (note 4) | 906 | 1,040 | NaN | NaN |
| Total current assets | 174,930 | 196,448 | 245,588 | 267,444 |
| Property and equipment, net (note 4) | 2,664 | 2,940 | 4,344 | 4,892 |
| Operating lease right-of-use assets (note 15) | 23,131 | 23,966 | 24,794 | 25,615 |
| Restricted cash | 1,482 | 1,482 | 1,482 | 1,482 |
| Other non-current assets | 389 | 392 | 392 | 391 |
| Total assets | 202,596 | 225,228 | 276,600 | 299,824 |
| Accounts payable | 362 | 480 | 485 | 1,384 |
| Accrued research and development | 4,141 | 4,804 | 7,779 | 10,790 |
| Accrued liabilities (note 6) | 4,143 | 9,634 | 8,173 | 7,192 |
| Operating lease liabilities, current (note 15) | 1,713 | 1,447 | 1,187 | 1,225 |
| Total current liabilities | 10,359 | 16,365 | 17,624 | 20,591 |
| Operating lease liabilities, non-current (note 15) | 27,071 | 27,658 | 28,231 | 28,791 |
| Long-term debt (note 7) | 0 | 0 | 30,439 | 30,360 |
| Total liabilities | 37,430 | 44,023 | 76,294 | 79,742 |
| Common stock, 0.0001 par value per share 300,000,000 shares authorized at march 31, 2026 and december 31, 2025 and 61,914,569 and 61,449,290 shares issued and outstanding at march 31, 2026 and december 31, 2025, respectively (note 9) | 6 | 6 | 6 | 6 |
| Additional paid-in capital | 1,044,937 | 1,040,610 | 1,036,085 | 1,029,595 |
| Accumulated deficit | -879,436 | -859,396 | -835,819 | -809,518 |
| Accumulated other comprehensive loss | -341 | -15 | 34 | -1 |
| Total stockholders equity | 165,166 | 181,205 | 200,306 | 220,082 |
| Total liabilities and stockholders equity | 202,596 | 225,228 | 276,600 | 299,824 |
PLIANT THERAPEUTICS, INC. (PLRX)
PLIANT THERAPEUTICS, INC. (PLRX)